Nothing Special   »   [go: up one dir, main page]

DE60330257D1 - Zusammensetzung zur impfung - Google Patents

Zusammensetzung zur impfung

Info

Publication number
DE60330257D1
DE60330257D1 DE60330257T DE60330257T DE60330257D1 DE 60330257 D1 DE60330257 D1 DE 60330257D1 DE 60330257 T DE60330257 T DE 60330257T DE 60330257 T DE60330257 T DE 60330257T DE 60330257 D1 DE60330257 D1 DE 60330257D1
Authority
DE
Germany
Prior art keywords
compositions
immunogen
methods
vaccination
occlusion vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330257T
Other languages
English (en)
Inventor
Nikolai Soren Kikrby
Peter Borman Samuelsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nordic Vaccine AS
Original Assignee
Coloplast AS
Nordic Vaccine Technology AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK200201473A external-priority patent/DK200201473A/da
Application filed by Coloplast AS, Nordic Vaccine Technology AS filed Critical Coloplast AS
Application granted granted Critical
Publication of DE60330257D1 publication Critical patent/DE60330257D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60330257T 2002-10-02 2003-10-02 Zusammensetzung zur impfung Expired - Lifetime DE60330257D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41510202P 2002-10-02 2002-10-02
DK200201473A DK200201473A (da) 2002-10-02 2002-10-02 Vaccinepræparater
PCT/DK2003/000654 WO2004030696A2 (en) 2002-10-02 2003-10-02 Composition for vaccination

Publications (1)

Publication Number Publication Date
DE60330257D1 true DE60330257D1 (de) 2010-01-07

Family

ID=32070988

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330257T Expired - Lifetime DE60330257D1 (de) 2002-10-02 2003-10-02 Zusammensetzung zur impfung

Country Status (9)

Country Link
EP (1) EP1545605B8 (de)
JP (1) JP2006503072A (de)
AT (1) ATE449612T1 (de)
AU (1) AU2003269839B2 (de)
CA (1) CA2500911A1 (de)
DE (1) DE60330257D1 (de)
DK (1) DK1545605T3 (de)
NZ (1) NZ539008A (de)
WO (1) WO2004030696A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2822049B1 (fr) 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
US7635488B2 (en) 2001-03-13 2009-12-22 Dbv Technologies Patches and uses thereof
US7887842B2 (en) 2003-02-07 2011-02-15 Teikoku Pharma Usa, Inc. Methods of administering a dermatological agent to a subject
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
CN101107009B (zh) 2005-01-20 2014-08-06 伊斯克诺瓦公司 包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
US20100047329A1 (en) * 2006-02-07 2010-02-25 Nippon Biologicals, Inc. Novel Vaccination Carrier
US20100136092A1 (en) * 2007-03-01 2010-06-03 Shinsaku Nakagawa Transdermal immune preparation, method for production of the same, and transdermal immunization method using the same
EP2116266A1 (de) * 2007-03-01 2009-11-11 Cosmed Pharmaceutical Co., Ltd. Perkutan resorbierbare zubereitung, verfahren zu ihrer herstellung und perkutanes resorptionsverfahren
FR2921562B1 (fr) * 2007-10-01 2012-06-15 Dbv Tech Dispositif adhesif pour application cutanee
FR2924350B1 (fr) 2007-12-03 2010-08-13 Dbv Tech Procede et compositions pour la vaccination par voie cutanee
FR2924349B1 (fr) 2007-12-03 2010-01-01 Dbv Tech Methode de desensibilitation aux allergenes
WO2009106085A1 (en) * 2008-02-28 2009-09-03 Nordic Vaccine A/S Vaccine compositions comprising saccharide antigens
US20110159035A1 (en) 2008-08-01 2011-06-30 Masahiro Goto S/o type transdermal immunizing agent
CA2796004C (en) * 2010-04-16 2020-09-22 Dbv Technologies Method of vaccination
JP5263349B2 (ja) * 2011-08-08 2013-08-14 生化学工業株式会社 生理活性分子含有架橋ヘパリンゲル組成物
JP6050822B2 (ja) 2011-10-03 2016-12-21 モレインクス，エービー ナノ粒子、ナノ粒子の調製のための処理、および癌治療および食品関連化合物を含む医療分野における両親媒性分子または疎水性分子ための担体としてのナノ粒子の使用
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
KR102484824B1 (ko) * 2020-09-03 2023-01-05 주식회사 중앙백신연구소 동물용 미끼백신 및 이의 제조방법
KR102621024B1 (ko) * 2023-09-12 2024-01-05 (주)진코스텍 심미감 및 피부 흡수력이 개선된 하이드로겔 패치

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
US5306504A (en) * 1992-12-09 1994-04-26 Paper Manufactures Company Skin adhesive hydrogel, its preparation and uses
AUPO517897A0 (en) * 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
DE69936355T2 (de) * 1998-02-25 2008-02-21 The Government Of The United States, As Represented By The Secretary Of The Army Verwendung von Hautpenetrationsförderern und für die Zerstörung der oberen Hautschichten geeigneten Mitteln zur Erhöhung der transkutanen Immunantwort
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
PT1031346E (pt) * 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
AU4188100A (en) * 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
GB9920167D0 (en) * 1999-08-25 1999-10-27 Avery Dennison Corp Pressure sensitive adhesive compositions
WO2002074325A1 (en) * 2001-03-19 2002-09-26 Iomai Corporation Patch for transcutaneous immunization
WO2002080981A2 (en) * 2001-04-04 2002-10-17 Nordic Vaccine Technology A/S Polynucleotide binding complexes comprising sterols and saponins

Also Published As

Publication number Publication date
WO2004030696A3 (en) 2004-05-06
ATE449612T1 (de) 2009-12-15
WO2004030696A8 (en) 2004-06-10
EP1545605A2 (de) 2005-06-29
DK1545605T3 (da) 2010-04-12
AU2003269839A1 (en) 2004-04-23
CA2500911A1 (en) 2004-04-15
EP1545605B8 (de) 2010-05-26
JP2006503072A (ja) 2006-01-26
EP1545605B1 (de) 2009-11-25
WO2004030696A2 (en) 2004-04-15
AU2003269839B2 (en) 2006-07-27
NZ539008A (en) 2006-10-27

Similar Documents

Publication Publication Date Title
DE60330257D1 (de) Zusammensetzung zur impfung
Castellan et al. Effect of dentin biomodification using naturally derived collagen cross‐linkers: One‐year bond strength study
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
ATE426412T1 (de) Adjuvante influenza-vakzine
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
ATE330967T1 (de) An her2 bindende peptidverbindungen
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BR0316758A (pt) Vacinas baseadas em levedura como imunoterapia
AU2002305450A1 (en) Proteomimetic compounds and methods
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
ATE350010T1 (de) Zusammensetzung zur topischen anwendung
Ricci et al. Wettability of chlorhexidine treated non‐carious and caries‐affected dentine
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
WO2008056174A3 (en) Novel compositions and uses thereof
WO2008057158A3 (en) Novel neutralizing immunogen (nimiv) of rhinovirus and its use for vaccine applications
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
Mews et al. Shear bond strength of orthodontic brackets to enamel after application of a caries infiltrant
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
DE602006015508D1 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs
ATE402211T1 (de) Verfahren zur herstellung von farblosen, lagerstabilen biuretgruppenhaltigen polyisocyanaten
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
SE9903534D0 (sv) Vaccin
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE60017793D1 (de) Verfahren zur vorbeugung und behandlung von beschädigung des schleimhautgewebes
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NORDIC VACCINE A/S, COPENHAGEN, DK

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1545605

Country of ref document: EP

Representative=s name: MICHALSKI HUETTERMANN & PARTNER PATENTANWAELTE, 40